Interleukin-2 gene transfer into human transitional cell carcinoma of the urinary bladder

被引：0
作者：
M Milella
J Jacobelli
F Cavallo
A Guarini
F Velotti
L Frati
R Foà
G Forni
A Santoni
机构：
[1] University of Rome ‘La Sapienza’,Department of Experimental Medicine and Pathology
[2] viale Regina Elena 324,Department of Biomedical Sciences and Human Oncology
[3] Consiglio Nazionale delle Ricerche-Centro Immunogenetica ed Oncologia Sperimentale,Department of Scienze Ambientali
[4] University of Turin,undefined
[5] University of Tuscia,undefined
来源：
British Journal of Cancer | 1999年 / 79卷
关键词：
human; interleukin-2; transitional bladder cancer; gene therapy; immunotherapy;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Transitional cell carcinoma of the bladder is one of the human cancers most responsive to immunotherapy, and local interleukin-2 (IL-2) production appears to be an important requirement for immunotherapy to be effective. In this study, we engineered two human bladder cancer cell lines (RT112 and EJ) to constitutively release human IL-2 by retroviral vector-mediated gene transfer. Following infection and selection, stable and consistent production of biologically active IL-2 was demonstrated at both the mRNA and the protein level. Morphology, in vitro growth rate and proliferation, as well as other cytokine gene mRNA or membrane adhesion receptor expression, were not altered in IL-2 transduced cells as compared to their parental or control vector-infected counterparts. Moreover, IL-2 engineered cells lost their tumorigenicity into nu/numice and the mechanism of rejection appeared to involve multiple host effector cell populations, among which a prominent role was played by neutrophils and radiosensitive cells. These findings may offer support to the development of an IL-2-based gene therapy approach to human bladder cancer.
引用
收藏
页码：770 / 779
页数：9
相关论文
共 276 条
[11]  
Siegal GP(1990)Improved retroviral vectors for gene transfer and expression Cell 60 397-403
[12]  
Anderson SC(1988)Interleukin-2 production by tumour cells bypasses T helper function in the generation of an anti-tumour response Prog Exp Tumor Res 32 187-212
[13]  
Maneval DC(1992)Tumor immunotherapy by local injection of interleukin-2 and non-reactive lymphocytes. Experimental and clinical results Blood 80 2817-2825
[14]  
Curiel DT(1992)Retroviral gene transfer induced constitutive expression of interleukin-2 or interferon-γ in irradiated human melanoma cells Cancer Res 52 6229-6236
[15]  
Cavallo F(1995)Retroviral vector-mediated lymphokine gene transfer into human renal cancer cells Blood 86 1170-1176
[16]  
Giovarelli M(1995)Effects of interleukin-2 on gene expression in human neutrophils Cytokines Mol Ther 1 57-64
[17]  
Gulino A(1996)IL-2 gene-transduced human HLA-A2 melanoma cells can generate a specific anti-tumour cytotoxic T-lymphocyte response Int J Oncol 8 765-772
[18]  
Vacca A(1997)Human lung carcinoma cells engineered to release IL-2, IL-7, GM-CSF, and TNF-α: growth in nu/nu mice and modulation of TGF-β 1 production Blood 89 212-218
[19]  
Stoppacciaro A(1995)Transfer of the interleukin-2 gene into human cancer cells induces specific anti-tumour recognition and restores the expression of CD3/T-cell receptor associated signal transduction molecules Int J Cancer 61 253-260
[20]  
Modesti A(1994)Rejection of mouse melanoma elicited by local secretion of interleukin-2: implicating macrophages without T cells or natural killer cells in tumor rejection Cancer 74 1904-1911
12345678910